A key factor in overcoming barriers to United States market entry is sharing the positive experiences of both healthcare professionals and patients, explained HoUng Kim, Head of Strategy and Operations Division, Celltrion Healthcare during a presentation at SMi Biosimilars USA Conference in Iselin, NJ, that took place November 14-15, 2018.
A key factor in overcoming barriers to United States market entry is sharing the positive experiences of both healthcare professionals and patients, explained HoUng Kim, Head of Strategy and Operations Division, Celltrion Healthcare during a presentation at SMi Biosimilars USA Conference in Iselin, NJ, that took place November 14-15, 2018.
In discussing the value of biosimilars to the healthcare system, Kim cited data from IMS Health that found that “biosimilars could lead to cumulative savings of up to $107 billion by 2020 in the United States and the top 5 European Union [EU] countries.” While the EU has been ahead of the curve when it comes to approving and prescribing biosimilars, the US market has been slower to generate uptake as the first product was approved some 10 years prior in the EU than in the United States.
Kim highlighted several challenges facing the US biosimilar market, such as physicians and patients alike lacking confidence in the products due to a “low level of education and awareness.” He discussed the results of 2 surveys that found that “67% of patients said they were ‘unaware’ of biosimilars,1 and when responding to the question ‘is a biosimilar safe?” 70% of patients said ‘no.’”2 In addition, he also mentioned the alleged “anti-biosimilar campaigns” that run in the United States as increasing the negative perception of biosimilars, as well as patent litigation that hinders biosimilars entering the market.
In discussing ways to address these market barriers, Kim emphasized that it’s not a task that can be accomplished by any one company alone. “In particular, it is important to highlight best practice[s] and work together to ensure as many patients as possible in the [United States] have access to treatment through the use of high quality, more cost-effective biosimilars,” he said.
When looking ahead to the future of the biosimilars market, Kim announced that Celltrion was looking forward to launching subcutaneous biosimilar infliximab next year. “We expect that this will generate further cost savings in addition to improved convenience as dual formulations would provide therapeutic approaches to optimize patient outcomes.”
References
1. Jacobs I, Singh E, Sewell KL, Al-sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross sectional survey. Patient Prefer Adherence. 2016;10:937-948.
2. Cohen H, Beydoun D, Chien D, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2016;33(12):2160-2172.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars
June 24th 2024Two posters from the American Society of Clinical Oncology (ASCO) annual meeting look at Medicare reimbursement trends for originator and biosimilar biologics, as well as a combination therapy utilizing a pegfilgrastim biosimilar in patients with advanced hepatocellular carcinoma.
EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris
Published: June 15th 2024 | Updated: June 14th 2024A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).